# Alector, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Alector, Inc.).

## Overview

Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases with high unmet medical need. Its programs are built around disease biology such as misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. The company’s approach combines antibody discovery, protein engineering, and genetically validated targets to try to change disease progression rather than only treat symptoms. Alector also develops its proprietary Alector Brain Carrier (ABC) platform, which is intended to improve delivery of therapeutics across the blood-brain barrier. The company has no approved drugs and currently relies on collaboration revenue, especially from its agreement with GSK, to fund development.

## Products & services

• Nivisnebart (AL101/GSK4527226) progranulin-elevating antibody
• Latozinemab neurodegenerative disease antibody program
• Alector Brain Carrier (ABC) blood-brain barrier platform
• Biomarker and biomarker assay development
• Collaborative R&D and licensing with GSK and prior partners

- **Clinical-stage therapeutic programs** (70%) — Investigational antibody-based programs for neurodegenerative diseases, including nivisnebart and latozinemab.
- **Platform technology** (10%) — The ABC platform designed to improve delivery of biologics and other modalities across the blood-brain barrier.
- **Collaborative research and development services** (20%) — R&D services performed under collaboration agreements, primarily with GSK, recognized over the development period.

- Nivisnebart (AL101/GSK4527226) progranulin-elevating antibody
- Latozinemab neurodegenerative disease antibody program
- Alector Brain Carrier (ABC) blood-brain barrier platform
- Biomarker and biomarker assay development
- Collaborative R&D and licensing with GSK and prior partners

## Customers

Alector does not sell approved medicines today, so its current economic counterparties are collaboration partners rather than end patients or hospitals. The most important customer-like relationship is with GSK, which funds and co-develops selected programs and may commercialize them in defined territories. The company also works with research and manufacturing partners such as Adimab and third-party contract manufacturers to advance discovery, development, and supply. If any product is approved in the future, the ultimate buyers would be physicians, payors, and healthcare systems treating neurodegenerative disease patients, but that commercial model has not started yet. In the near term, value creation depends on partners paying for licenses, development milestones, and future royalties or profit-sharing.

- **Pharmaceutical collaboration partner** (primary) — GSK co-develops selected programs, funds part of development, and may commercialize products in and outside the U.S.
- **Research and manufacturing partners** (secondary) — Specialized third parties such as Adimab and contract manufacturers support discovery, development, and supply execution.
- **Future healthcare providers and payors** (emerging) — If approved, neurologists, hospitals, and payors would buy or reimburse therapies for neurodegenerative disease treatment.
- **Patients and caregivers** (emerging) — The eventual end users of therapies for Alzheimer’s disease and other neurodegenerative conditions.

- GSK as the main collaboration partner funding and co-developing programs
- Other biotech/pharma partners for licensing and discovery support
- Contract manufacturers providing drug product and development manufacturing services
- Future physicians and payors would be the end-market buyers if products are approved
- Patients with neurodegenerative diseases are the ultimate therapeutic end users

## Geography

Alector is headquartered in South San Francisco, California, and its business is managed from the United States. The company’s current revenue base is tied primarily to the GSK collaboration, with the agreement explicitly splitting commercialization rights between the United States and the rest of the world. In the United States, Alector and GSK would share profits and losses equally on covered products, while outside the United States GSK would handle commercialization and Alector would receive tiered royalties. Because the company is still clinical-stage, geography matters more through partner rights, development responsibilities, and future commercialization economics than through a broad operating footprint. The company also depends on global third-party manufacturers and collaborators, which adds cross-border execution and regulatory complexity.

- Headquartered in South San Francisco, California
- United States is the key market for shared commercialization economics
- Outside the United States, GSK controls commercialization and Alector earns royalties
- Development and manufacturing rely on third-party partners rather than owned plants
- Global regulatory and supply-chain execution will matter if programs advance

## Strategy

Alector’s strategy is to advance genetically validated programs for neurodegenerative disease while improving the odds of technical success through biomarker-guided development. A major pillar is the ABC platform, which is intended to solve the blood-brain barrier delivery problem that limits many CNS therapies. The company is also prioritizing capital discipline, including a workforce reduction, to align spending with its current pipeline and extend runway into the second half of 2027. Collaboration remains central to the model, with GSK providing funding, development support, and future commercialization capabilities. The company continues to seek additional financing and may use partnerships, licensing, or capital markets access to support long-duration R&D.

- **Advance nivisnebart and latozinemab through clinical development** (short-term) — Clinical progress is the main driver of value because the company has no approved products and depends on pipeline success.
- **Expand biomarker-driven development capabilities** (medium-term) — Biomarkers can improve target engagement, patient selection, and the probability of technical success in CNS trials.
- **Preserve capital and extend runway** (short-term) — The company needs to fund multi-year R&D while avoiding excessive dilution or premature commercialization spending.
- **Leverage partnerships for development and commercialization** (medium-term) — External partners reduce the need to build a full commercial organization before product approval.

- Advance neurodegenerative disease programs with genetically validated targets
- Use biomarker assays to improve patient selection and proof of mechanism
- Develop the ABC platform to improve brain delivery across modalities
- Rely on GSK and other partners for development and commercialization leverage
- Preserve cash through workforce reductions and tighter operating alignment
- Maintain flexibility to raise capital or sign additional collaborations

## Risks

Alector faces the classic risks of a clinical-stage biotechnology company: no approved products, no product sales, and a long path to proving clinical efficacy and safety. Its business depends heavily on third-party collaborators and manufacturers, so delays, termination rights, quality issues, or underperformance by partners could materially slow development or disrupt supply. The company also expects to continue incurring losses and will need additional capital in the future, creating financing and dilution risk if markets are weak or trial results disappoint. In neurodegenerative disease, clinical endpoints are difficult to move, patient selection is challenging, and regulatory approval standards are high, which increases the chance of late-stage failure. Because a large share of future value is tied to the GSK agreement, any change in that relationship would have an outsized impact on economics and strategic flexibility.

- **Clinical development failure** [critical] — The company is still testing investigational therapies, and efficacy or safety setbacks could eliminate program value.
- **Dependence on collaboration partners** [high] — A large portion of expected revenue and development execution depends on GSK and other third parties.
- **Financing and dilution risk** [high] — The company expects to need substantial additional funding for R&D and operations beyond current runway.
- **Manufacturing and supply-chain risk** [high] — Alector relies on contract manufacturers and development manufacturing services rather than owned production assets.
- **Commercialization uncertainty** [medium] — The company has no sales or marketing infrastructure and would need to build or outsource it if products are approved.

- No approved products, so the company has no commercial revenue base
- Clinical trial failure risk is high in neurodegenerative disease
- Dependence on GSK and other collaborators creates partner concentration risk
- Third-party manufacturing can create quality, supply, and regulatory risk
- Future financing needs could dilute shareholders or be unavailable on good terms
- Commercialization execution risk is high if products are approved
- Biomarker and patient-selection uncertainty can weaken trial outcomes

## Accounting

Alector’s most important accounting issue is revenue recognition from collaboration agreements, especially the GSK arrangement, where upfront consideration and development services are recognized over time or at a point in time depending on the performance obligation. Deferred revenue is material and is recognized over the research and development period, so reported revenue can lag cash receipts and move with program progress rather than product demand. Because the company has no product sales, quarterly revenue can be volatile and heavily influenced by collaboration milestones, license timing, and the pace of R&D spend used to measure service completion. Investors should also watch estimates around accrued R&D, stock-based compensation, and any impairment or valuation judgments tied to collaboration assets or capitalized items, since these can materially affect reported losses. As a clinical-stage biotech, the company’s accounting is less about inventory and receivables and more about contract accounting, estimate sensitivity, and the timing of expense recognition versus cash usage.

- **Collaboration revenue recognition** — Can shift revenue between periods without changing underlying cash receipts
- **Deferred revenue** — Creates a large balance sheet liability and future revenue visibility
- **Accrued research and development expenses** — Can affect quarterly operating loss and comparability
- **Stock-based compensation** — Increases reported operating expenses and reduces comparability to cash burn

- Collaboration revenue recognition under the GSK agreement
- Deferred revenue roll-forward and timing of recognition
- Point-in-time versus over-time recognition for licenses and R&D services
- Quarterly volatility from milestones and development progress
- Accrued R&D and third-party service estimates
- Stock-based compensation and other non-cash operating expenses

---

*Last updated: 2026-08-11T04:46:19.922409+00:00*